MedInsights Unleashed  Por  arte de portada

MedInsights Unleashed

De: MedInsights Unleashed
  • Resumen

  • The MedInsights Unleashed Podcast aims to break down complex clinical data to provide insights from cutting-edge developments into tangible benefits for physicians, patients, and caregivers around the globe. Zee Ramji and John Collins will engage with leading global healthcare specialists to bring the latest groundbreaking therapies to you. To learn more about Zee and John, go deeper into each episode and access additional resources, go to https://medinsightsunleashed.com
    Más Menos
Episodios
  • Making a Difference in Healthcare: Zee and John's story
    Apr 19 2024

    In their debut episode, John Collins and Zahra, also known as Zee, introduce themselves and their backgrounds in the pharmaceutical industry and healthcare. With a focus on filling the void between physicians and patients, they share their passion for improving patient outcomes, particularly in underserved areas like liver cancer. John draws parallels from his experience as an EMS first responder, emphasizing the importance of rapid knowledge transfer in saving lives. Zahra discusses her work in clinical trials and oncology, highlighting the desire to make a tangible difference in patients' lives. Together, they embark on a journey through the MedInsights Unleashed podcast to uncover global healthcare trends and empower patients with valuable insights.

    Más Menos
    7 m
  • MedInsights Unleashed_Trailer
    May 3 2024

    Trailer for MedInsights Unleashed with Zee and John, starring co-hosts Zahra Ramji (aka Zee) and John Collins

    Más Menos
    2 m
  • The Promise and Limitations of Adjuvant Treatment in Liver Cancer with Prof Arndt Vogel
    May 31 2024

    MedInsights Unleashed is an exciting new podcast aimed at providing valuable information and insights for patients and healthcare professionals.

    In this first episode, hosts Zahra and John are joined by Professor Arndt Vogel to discuss key data from the adjuvant setting of liver cancer. They talk about the challenges of liver cancer treatment, the high mortality rate associated with the disease, and the progress made in recent years.

    Professor Vogel provides an overview of the IMbrave 050 study, which was designed to investigate the efficacy of an adjuvant treatment combination of the checkpoint inhibitor atezolizumab and the targeted therapy bevacizumab in delaying or preventing recurrence compared with active surveillance. The study shows promising results in terms of improved recurrence-free survival, but longer follow up is needed to determine its impact on overall survival. The conversation also touches on the safety profile of the treatment and the importance of multidisciplinary teams in decision-making.

    Más Menos
    28 m

Lo que los oyentes dicen sobre MedInsights Unleashed

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.